Loading
Pentixapharm Holding AG Stock: price and insider trades · Germany
No insider purchase over the last 90 days. The latest was filed 27 Nov 2025.
Pentixapharm Holding AG: what insiders have been doing
Pentixapharm Holding AG, classified in the Healthcare & Pharma sector, is a listed company based in Würzburg, Germany, founded in 2019. Its insiders report their share dealings to BaFin. The last twelve months, up to 18 October 2026, brought 4 filings signed by 2 insiders.
Every open-market trade in the period is a purchase: 2 purchases worth €202k, from 1 insider, and not a single sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €103k by Eckert Wagniskapital und Frühphasenfinanzierung GmbH, published on 6 November 2025.
Compared with its exchange (287 companies, median 5 filings), a count of 4 filings is below the norm. Looking back to 2025, when coverage begins, insiders filed 4 purchases and no sales.
The most recent open-market purchase was published on 27 November 2025, 324 days ago. Between a trade and the moment it shows up on BaFin, the median delay is 2 days. Under the Market Abuse Regulation, managers have three business days to notify their trades.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by BaFin. They describe what insiders did and are not a recommendation.
Key facts
Headquarters: Würzburg, Germany · Founded: 2019
Source: Wikidata (CC0).
Insider Decl.
6
Thresholds
n/a
Buy Volume
€548,416
4 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleEckert Wagniskapital und Frühphasenfinanzierung GmbH5 buys
Financial data
as of FY 2025FY ended December 2025 · cache
€1.82
Analyst consensus
2 analysts1.00/5
€7.20Target €9.27(+409%)€11.33
Income statement
Revenue€93k
Gross profit-€6.7M-7208% margin
EBITDA-€15.8M-16971% margin
Net income-€16.5M-17753.8% margin
Valuation
PER (forward)-2.8x
P/Book1.6x
Beta1.46
Balance sheet & cash
Market cap€910k
Free Cash Flow-€18.6M
Profitability & ownership
ROE-43.3%
ROA-24.8%
% insiders31.0%
% institutions6.1%
Last declaration on 21 August 2026
Declarations6 total
3,965,539 shares@ €1.85ShareISIN DE000A40AEG0BAFIN:50090404-f878e1616cda
0Other financial instr. linked to share;debt instr.ISIN DE000A41YFP6BAFIN:50090404-fecd5ee4b03f
70,923.929 shares@ €1.4018.1% of flowShareISIN DE000A40AEG0BAFIN:50090404-49521793ff3d
Canonical exit: 24 Feb 2026 (T+90)
64,856.918 shares@ €1.5918.8% of flowShareISIN DE000A40AEG0BAFIN:50090404-a4afd06309c5
Canonical exit: 3 Feb 2026 (T+90)
179,000 shares@ €1.5049.0% of flowShareISIN DE000A40AEG0BAFIN:50090404-2781f068b4b6
Canonical exit: 14 Dec 2025 (T+90)
50,000 shares@ €1.5514.1% of flowShareISIN DE000A40AEG0BAFIN:50090404
Canonical exit: 10 Dec 2025 (T+90)
6 of 6 declarations
About Pentixapharm Holding AG
Pentixapharm Holding AG is a German clinical-stage biotechnology company listed on Xetra/Frankfurt (DAX/MDAX/SDAX) under ticker PTP.DE and ISIN DE000A40AEG0. Headquartered in Berlin, Germany, the company was founded in 2019 and emerged from a spin-off of the Eckert & Ziegler group before listing on the Frankfurt Stock Exchange’s Prime Standard on 3 October 2024. For international investors, Pentixapharm sits in a high-science, high-risk segment of healthcare: radiopharmaceuticals.
The company’s business model is built around innovative radiopharmaceuticals for diagnosis and therapy, following a theranostics approach that links imaging with targeted treatment. Its pipeline is centered on CXCR4-targeted assets, a biologically relevant receptor implicated in several high-unmet-need diseases. The lead diagnostic candidate is PentixaFor, a gallium-68-labeled radiodiagnostic designed to support non-invasive subtyping of primary aldosteronism in patients with treatment-resistant hypertension. On the therapeutic side, PentixaTher is a yttrium-90-based radiopharmaceutical being developed for oncology applications. Pentixapharm is also advancing an antibody-based radiolabeled platform at an earlier, preclinical stage.
Read moreShow less
From a competitive standpoint, Pentixapharm operates in a specialized but strategically attractive niche. Radiopharmaceuticals combine strong scientific differentiation, high barriers to entry, and the potential for meaningful clinical and commercial value if development succeeds. The company’s positioning rests on first-in-class CXCR4-targeted programs, a growing body of clinical publications, and an increasingly visible regulatory path, especially in the United States. Its geographic footprint is primarily German, with offices in Berlin and Würzburg, while its development and regulatory ambition is clearly international.
Recent company-specific news has been important. In May 2026, Pentixapharm submitted an IND application to the U.S. FDA to initiate the Phase 3 PANDA study for its lead CXCR4-targeted diagnostic program. The company also reported favorable FDA feedback on that program, which supports its registrational strategy. In 2026, Pentixapharm also received “Study May Proceed” letters for dual theranostic INDs in its CXCR4-based hematology-oncology program. In 2025, it signed a manufacturing agreement with Eckert & Ziegler for Y90-PentixaTher and subsequently announced a strategic shift to reduce early-stage R&D and focus resources on its most advanced clinical assets. Overall, Pentixapharm offers exposure to a German listed healthcare name on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany, with substantial pipeline optionality but clear clinical and regulatory execution risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
